The Next Frontier in Women’s Health Genetic Testing
From prenatal genetic testing to earlier cancer recurrence detection with novel molecular residual disease testing, Natera is innovating our technology to enable better outcomes in women’s health.
Pioneering NIPT technology now applied to cancer recurrence detection and monitoring
The unique SNP-based technology that distinguishes maternal from fetal cell-free DNA (cfDNA) has now been adapted to detect circulating tumor DNA (ctDNA) with Natera’s tumor-specific assay Signatera™. Cancer cells release ctDNA into the bloodstream, which can be measured to assess the presence of residual disease. This molecular residual disease test (MRD) is used to detect cancer recurrence and monitor treatment response.
Trusted expertise adapted to detect tumor DNA
See how Natera’s ctDNA test, Signatera™ works
Transforming management in women’s cancers
Signatera™, Natera’s molecular residual disease test (MRD), was the first tumor-specific assay for individualized cancer care. It enables earlier recurrence detection and ongoing surveillance in breast and gynecological cancers.
10.5 months earlier
median lead time in breast cancer recurrence detection over standard imaging1
2x the sensitivity
in detecting ovarian cancer relapse compared to CA-125, the most commonly used biomarker for ovarian cancer2,3As early as 6 weeks
into treatment to identify response to immunotherapy in gynecologic cancers4Impacting outcomes for women’s cancers
Angela’s Story
Like many patients, Angela has faced many questions throughout her journey with high risk breast cancer – what’s the next step in my treatment? Is the cancer ever going to come back? What’s causing this symptom?
Listen to the story of how she asked her doctor about Signatera™ to help monitor for recurrence and treatment response, giving her the peace of mind to move on with her life.
Most extensively validated MRD test
Signatera™ has published 65+ peer-reviewed studies across multiple indications, including colorectal, bladder, lung, breast, and gynecologic cancers.
Lajos Pusztai, MD, DPhil
Professor of Medicine (Medical Oncology); Co-Leader, Genetics, Genomics and Epigenetics Research Program, Yale Cancer Center, Yale School of Medicine
Most extensively validated MRD test
Signatera™ has published 65+ peer-reviewed studies across multiple indications, including colorectal, bladder, lung, breast, and gynecologic cancers.
Lajos Pusztai, MD, DPhil
Professor of Medicine (Medical Oncology); Co-Leader, Genetics, Genomics and Epigenetics Research Program, Yale Cancer Center, Yale School of Medicine
Investing in innovations in personalized genetic testing
R&D INVESTMENTS
400 MILLION
PEER-REVIEWED PUBLICATIONS
200+
PATIENT SAMPLES
10 MILLION
Source: Internal Natera Data
Learn more about Natera’s latest innovations
1Shaw JA, et al. Serial postoperative ctDNA monitoring for early detection of breast cancer recurrence. Poster presented at: ASCO; June 3-7, 2022; Chicago, IL.
2Hou et al. Gynecol Oncol. 2022; 167:334-341
3Chapman et al. Poster presented at 2021 AACR Annual Meeting.
4Bratman et al. Nature Cancer. 2020; 1(9):873-881.